![]() |
市場調查報告書
商品編碼
1750766
Frost Radar:RWE 生命科學解決方案 2025Frost Radar: Life Sciences Real-World Evidence Solutions, 2025 |
基準化分析系統激勵主要企業-創新推動新的交易流程和成長管道
不斷發展的IT格局在生命科學領域發揮了變革性作用,使得對RWE解決方案的依賴成為可能。隨著競爭日益激烈以及對決策精準度的需求不斷成長,製藥公司、醫療保健提供者和科技公司逐漸意識到,RWD技術在促進研究、最佳化臨床試驗和改善患者療效方面非常重要。
該平台和實行技術製藥和生物技術公司在整個產品生命週期中利用監管級 RWE,包括早期研究、臨床開發、發布計劃、基於價值的合約、縱向病患監測和患者活化。
生命科學 RWE 解決方案產業較為分散,約有 120 家供應商在資料聚合、整合、互通性和預測分析等領域開展業務,為製藥公司提供高品質的見解。
Frost & Sullivan 篩選並分析了超過 45 家 RWE 解決方案供應商,透過深入分析這些供應商的成長潛力及其推動行業前瞻性創新的能力,最終列出了 16 家主要企業。 Frost Radar™ 主要對資料整合、管理、分析和洞察領域的公司進行基準測試,並在資料收集領域擁有強大的影響力。其他領域的解決方案和實行技術對評估產生了積極影響。
在對供應商進行基準測試時,Frost & Sullivan 會根據關鍵標準評估每個供應商的產品組合,包括資料整合、資料品質、高級分析、可擴展性、即時存取、雲端支援、協作、監管專業知識、以患者為中心的方法、創新、敏捷性和成本效益,使生命科學公司能夠與最適合其不斷發展的客製化需求的供應商合作。
Frost & Sullivan 會分析同一產業內大量的公司。根據領導力和其他特徵,篩選出需要進一步分析的公司,並根據 10 項成長和創新標準進行基準測試,以揭示其在 Frost Radar™ 上的排名。 Frost Radar™ 上每家公司的競爭概況都會進行展示,探討其優勢以及最契合這些優勢的商業機會。
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) to boost research while optimizing clinical trials and improving patient outcomes.
The platforms and enabling technologies help pharma/biotech companies harness regulatory-grade RWE across the product lifecycle, including early-stage research, clinical development, launch planning, value-based contracting, long-term patient monitoring, and patient activation.
The life sciences RWE solutions industry is fragmented, with about 120 vendors operating in this space across areas including data aggregation, integration, interoperability, and predictive analytics to provide pharmaceutical companies with high-quality insights.
Frost & Sullivan screened and analyzed more than 45 RWE solution vendors and short-listed the leading 16 companies based on a detailed analysis of their corporate growth potential and ability to drive visionary innovation in this industry. This Frost Radar™ benchmarks companies primarily in data integration, management, analytics, and insights with a strong play in the data collection segment. Solutions in other segments and enabling technologies had a positive impact on their ratings.
When benchmarking vendors, Frost & Sullivan evaluated their portfolios across key criteria, such as data integration, data quality, advanced analytics, scalability, real-time access, cloud support, collaboration, regulatory expertise, patient-centric approaches, innovation, agility, and cost-effectiveness to ensure that life sciences companies partner with the best vendor for their evolving and customized needs.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.